TOXICOLOGICAL PROFILE FOR CHROMIUM - Davidborowski.com
TOXICOLOGICAL PROFILE FOR CHROMIUM - Davidborowski.com TOXICOLOGICAL PROFILE FOR CHROMIUM - Davidborowski.com
CHROMIUM 1602. HEALTH EFFECTSFigure 2-4. A Physiologically Based Model of Chromium Kinetics in the Rat*POOL BINHALATIONEXPOSURELUNGPOOL ACr(VI) Cr(III)WELL PERFUSEDCr(VI) Cr(III)PLASMAPOORLY PERFUSEDCr(VI) Cr(III)BONECr(VI) Cr(III)PLASMARED CELLSCr(VI) Cr(III)LIVERCr(VI) Cr(III)GI TRACTCr(VI) Cr(III)ORALEXPOSUREURINARYEXCRETIONKIDNEYCr(VI) Cr(III)RETAINEDURINEFECALEXCRETION*O’Flaherty 1996
CHROMIUM 1612. HEALTH EFFECTSincorporation of chromium into actively mineralizing bone. It also includes the reductive process forconversion of chromium(VI) to chromium(III) and takes into account differences in their absorptionthrough tissues of the body as well as in the lung and gastrointestinal tract. The chromium model neededto be modified to include two lung compartments. Chromium via inhalation or intratracheal routes entersthe lung in compartment A where it can be systemically absorbed, transferred to the second lungcompartment B, or cleared by mucociliary action and enter the digestive tract. Chromium enteringcompartment B can only be cleared by mucociliary action, and no chromium re-enters compartment Afrom B. In order to account for the urinary excretion delay observed in the experimental data, a urinaryretention compartment was added. Because the absorption of chromium compounds into the body andvarious tissues depends on the type and solubility of the complexes formed with ligands, adjustments tothe model must be made based on physicochemical characteristics of individual chromium compounds.Validation of the model. The model was run with the exposure regimen of an inhalation study ofchromium(VI) as zinc chromate dust in Wistar rats (Langård et al. 1978). This study was chosen forvalidation because none of the studies used to develop the model were inhalation studies. Rats wereexposed to 2.1 mg chromium(VI)/m 3 for 6 hours/day for 4 days, blood chromium was measured beforeand after each exposure and 4 times over the next 37 days post-exposure. The model tended tooverpredict chromium blood levels during the 4-day exposure period, but agreement during the postexposureperiod was good. The exposure conditions of a drinking water exposure to potassiumchromate(VI) for 1 year at concentrations of 045, 2.2, 4.5, 7.7, 11.2, and 25 ppm in Sprague-Dawley ratswere also simulated (MacKenzie et al. 1958).The model overestimated final liver chromium concentrations, but bone and kidney concentrations werewell-predicted. This was not a completely independent test of the model’s validity since data from thisstudy were used to set parameters for fractional uptake of chromium into bone.Target tissues. Tissue levels of chromium(III) and chromium(VI) in the rat lung, erythrocyte, liver,and kidney can be predicted by this model.Species extrapolation. No species extrapolation was attempted in this model. The model is basedentirely on data from rat kinetic studies.
- Page 130 and 131: TABLE 2-3. Levels of Significant Ex
- Page 132 and 133: HumanHumanHumanHumanHumanHumanHuman
- Page 134 and 135: CHRONIC EXPOSURESystemicHuman 7.5 y
- Page 136 and 137: CHROMIUM 1162. HEALTH EFFECTSNo stu
- Page 138 and 139: CHROMIUM 1182. HEALTH EFFECTSIrrita
- Page 140 and 141: CHROMIUM 1202. HEALTH EFFECTSindust
- Page 142 and 143: CHROMIUM 1222. HEALTH EFFECTSGuinea
- Page 144 and 145: CHROMIUM 1242. HEALTH EFFECTSmodel,
- Page 146 and 147: CHROMIUM 1262. HEALTH EFFECTSblood,
- Page 148 and 149: CHROMIUM 1282. HEALTH EFFECTSchromi
- Page 150 and 151: CHROMIUM 1302. HEALTH EFFECTSAlthou
- Page 152 and 153: CHROMIUM 1322. HEALTH EFFECTS2.3.2
- Page 154 and 155: CHROMIUM 1342. HEALTH EFFECTS2.3.2.
- Page 156 and 157: CHROMIUM 1362. HEALTH EFFECTSThe di
- Page 158 and 159: CHROMIUM 1382. HEALTH EFFECTS(2-5 m
- Page 160 and 161: CHROMIUM 1402. HEALTH EFFECTSIn rat
- Page 162 and 163: CHROMIUM 1422. HEALTH EFFECTSunstab
- Page 164 and 165: CHROMIUM 1442. HEALTH EFFECTSIn add
- Page 166 and 167: CHROMIUM 1462. HEALTH EFFECTSsignif
- Page 168 and 169: CHROMIUM 1482. HEALTH EFFECTS2.3.4.
- Page 170 and 171: CHROMIUM 1502. HEALTH EFFECTSDaily
- Page 172 and 173: CHROMIUM 1522. HEALTH EFFECTS51 Chr
- Page 174 and 175: CHROMIUM 1542. HEALTH EFFECTS2.3.5
- Page 176 and 177: CHROMIUM 1562. HEALTH EFFECTSFigure
- Page 178 and 179: CHROMIUM 1582. HEALTH EFFECTSTable
- Page 182 and 183: CHROMIUM 1622. HEALTH EFFECTSInterr
- Page 184 and 185: CHROMIUM 1642. HEALTH EFFECTSthe bl
- Page 186 and 187: CHROMIUM 1662. HEALTH EFFECTSpreval
- Page 188 and 189: CHROMIUM 1682. HEALTH EFFECTS2.5 RE
- Page 190 and 191: CHROMIUM 1702. HEALTH EFFECTSSevera
- Page 192 and 193: CHROMIUM 1722. HEALTH EFFECTSanimal
- Page 194 and 195: CHROMIUM 1742. HEALTH EFFECTSOral M
- Page 196 and 197: CHROMIUM 1762. HEALTH EFFECTSfibros
- Page 198 and 199: CHROMIUM 1782. HEALTH EFFECTSNausea
- Page 200 and 201: CHROMIUM 1802. HEALTH EFFECTSthe pr
- Page 202 and 203: CHROMIUM 1822. HEALTH EFFECTSSevere
- Page 204 and 205: CHROMIUM 1842. HEALTH EFFECTSdevelo
- Page 206 and 207: CHROMIUM 1862. HEALTH EFFECTSthe ce
- Page 208 and 209: CHROMIUM 1882. HEALTH EFFECTSimprov
- Page 210 and 211: CHROMIUM 1902. HEALTH EFFECTSchroma
- Page 212 and 213: CHROMIUM 1922. HEALTH EFFECTSIn ano
- Page 214 and 215: Table 2-5. Genotoxicity of Chromium
- Page 216 and 217: Table 2-5. Genotoxicity of Chromium
- Page 218 and 219: Species (test system)Prokaryotic or
- Page 220 and 221: Species (test system)S. typhimurium
- Page 222 and 223: Species (test system)Mouse A18BcR c
- Page 224 and 225: Species (test system)Prokaryotic or
- Page 226 and 227: Species (test system)Syrian hamster
- Page 228 and 229: CHROMIUM 2082. HEALTH EFFECTSet al.
<strong>CHROMIUM</strong> 1612. HEALTH EFFECTSincorporation of chromium into actively mineralizing bone. It also includes the reductive process forconversion of chromium(VI) to chromium(III) and takes into account differences in their absorptionthrough tissues of the body as well as in the lung and gastrointestinal tract. The chromium model neededto be modified to include two lung <strong>com</strong>partments. Chromium via inhalation or intratracheal routes entersthe lung in <strong>com</strong>partment A where it can be systemically absorbed, transferred to the second lung<strong>com</strong>partment B, or cleared by mucociliary action and enter the digestive tract. Chromium entering<strong>com</strong>partment B can only be cleared by mucociliary action, and no chromium re-enters <strong>com</strong>partment Afrom B. In order to account for the urinary excretion delay observed in the experimental data, a urinaryretention <strong>com</strong>partment was added. Because the absorption of chromium <strong>com</strong>pounds into the body andvarious tissues depends on the type and solubility of the <strong>com</strong>plexes formed with ligands, adjustments tothe model must be made based on physicochemical characteristics of individual chromium <strong>com</strong>pounds.Validation of the model. The model was run with the exposure regimen of an inhalation study ofchromium(VI) as zinc chromate dust in Wistar rats (Langård et al. 1978). This study was chosen forvalidation because none of the studies used to develop the model were inhalation studies. Rats wereexposed to 2.1 mg chromium(VI)/m 3 for 6 hours/day for 4 days, blood chromium was measured beforeand after each exposure and 4 times over the next 37 days post-exposure. The model tended tooverpredict chromium blood levels during the 4-day exposure period, but agreement during the postexposureperiod was good. The exposure conditions of a drinking water exposure to potassiumchromate(VI) for 1 year at concentrations of 045, 2.2, 4.5, 7.7, 11.2, and 25 ppm in Sprague-Dawley ratswere also simulated (MacKenzie et al. 1958).The model overestimated final liver chromium concentrations, but bone and kidney concentrations werewell-predicted. This was not a <strong>com</strong>pletely independent test of the model’s validity since data from thisstudy were used to set parameters for fractional uptake of chromium into bone.Target tissues. Tissue levels of chromium(III) and chromium(VI) in the rat lung, erythrocyte, liver,and kidney can be predicted by this model.Species extrapolation. No species extrapolation was attempted in this model. The model is basedentirely on data from rat kinetic studies.